Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins
about
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsVault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of miceIs there a role for plant-made vaccines in the prevention of HIV/AIDS?Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.The influence of delivery vectors on HIV vaccine efficacyA single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsIntranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced diseaseMatrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cellsThe synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)DNA vaccines against human immunodeficiency virus type 1 in the past decade.The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceFunctional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivoMucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virusNaloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesHighly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.Polyvalent AIDS vaccines.Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsPrime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodesLentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice.
P2860
Q28394899-D14C2968-BBF6-433E-99F0-4D4C5505476DQ28727249-502A1358-8251-484B-A94E-5EFA396F531FQ30350670-23D3872E-67E6-4939-AF02-8D94C6A4ECA5Q30385999-1051A519-C4C1-4128-8A39-FA3365BCC6A8Q33940220-0433882A-8620-4AB3-8133-F5DB393796F4Q34077543-F2078679-A6FC-4B8E-B8A8-3BC5E157B544Q34092753-7CECDB82-AEAC-4202-B4A5-008E96856ED0Q34228558-1D4A3BD2-17FA-438D-9946-818DA9787A7AQ34344372-51A8730B-C7F3-4555-BF28-829F82C9E4A1Q34434660-0A3C4FEB-28C0-4494-9418-6F30C1EE9FF8Q34614953-EE8B6595-34B8-42D0-9F52-897E5F555947Q34802680-E4DA6D20-5244-497D-9AF2-3B522AE497A0Q35076961-3FAB920C-5E51-481A-8B86-D5FCD261ED51Q35740733-2B7A70B2-7B01-4F45-A282-0F27764611C9Q35745831-9E532704-88E9-46B1-AC32-29D3E8556E02Q35867988-861EAE89-C389-4C93-B342-2A748F435BD1Q35883032-83618DDA-AAE5-411C-B5C3-998AC4F179F6Q36423935-29C1455D-3069-4C7B-9518-D45F8EEFABE2Q36474235-D3008A4C-762F-431C-AA75-026B3C567936Q36640081-2D41A786-C312-4E3F-9E44-89414490732EQ36672543-5C99DC6D-00C6-412D-9EB3-A03E778D6EBCQ36898706-7BDE3E54-E309-4F99-B84A-B09E0D9EB901Q36933020-952ED90A-82F1-496C-8631-580861079ED8Q36943971-9B26727C-0B58-4F70-9068-F9F90E30613BQ36972226-A778396E-EC49-4C64-9DD0-241323DE919AQ37094160-37294EDC-CDA4-4B5F-9944-C40554EDA07EQ37094429-09D12A4D-2CF1-4934-A327-6AD2D9C497D7Q37107609-6263D46C-5B36-4FC0-9D25-9861CE3D33C1Q37243886-BBA72C5A-8A59-4A91-B370-6483FDCE4E1AQ38363535-BF647717-0B06-48D4-8CD6-A889E394EA42Q39756926-D1D5265A-0CE8-4733-93B2-68277AA67C81Q41661161-12A994B9-AA6C-4938-9B5D-0217F60A5B2BQ54364542-A31C0FE6-3C6F-4ACD-BF8D-27869A6DC6DF
P2860
Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@ast
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@en
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@nl
type
label
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@ast
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@en
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@nl
prefLabel
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@ast
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@en
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@nl
P2093
P2860
P1433
P1476
Robust recall and long-term me ...... us type 1 Gag and Env proteins
@en
P2093
Eric Pamer
Ingrid Leiner
John K Rose
Karl Haglund
Kristen Kerksiek
Linda Buonocore
P2860
P304
P356
10.1128/JVI.76.15.7506-7517.2002
P407
P577
2002-08-01T00:00:00Z